Estrella Immunopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESLA research report →
Price Chart
About the company
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia.
- CEO
- Cynthia Pussinen
- IPO
- 2021
- Employees
- 3
- HQ
- EmeryVille, CA, US
Get TickerSpark's AI analysis on ESLA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.11M
- P/E
- -1.19
- PEG
- -0.09
- P/S
- 0.00
- P/B
- -1.06
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 136.00%
- ROIC
- 89.36%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,062,674
- Net Income
- $-13,063,512-47.6%
- EPS
- $-0.35-45.8%
- OCF Growth
- +42.6%
- FCF Growth
- +42.6%
- 52W High
- $2.27
- 52W Low
- $0.24
- 50D MA
- $0.51
- 200D MA
- $0.94
- Beta
- 0.89
- RSI (14)
- 41
- Avg Volume
- 2.04M
No earnings-call transcripts are available for ESLA yet.
- Free Float
- 39.6%
- Shares Outstanding
- 43.97M
- Float Shares
- 17.40M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 3.98M | ▼ 123.78K |
| Vanguard Group Inc | 448.76K | ▲ 29.05K |
| Vanguard Capital Management LLC | 416.85K | 0 |
| Geode Capital Management, LLC | 141.14K | ▼ 183 |
| Vanguard Fiduciary Trust Co | 94.40K | ▲ 29.48K |
| Blackrock, Inc. | 52.87K | ▲ 836 |
| State Street Corp | 43.25K | 0 |
| Northern Trust Corp | 34.86K | ▲ 15.24K |
| Renaissance Technologies LLC | 14.70K | ▼ 24.40K |
| Citigroup Inc | 5.91K | ▲ 5.91K |
| Tower Research Capital LLC (Trc) | 3.31K | ▼ 1.55K |
| Ubs Group AG | 1.36K | ▼ 365 |
Held by 22 ETFs
Biggest fund positions in ESLA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Pussinen Cynthia | other | 1,000,000 |
| Oct 25, 26 | Pussinen Cynthia | other | 0 |
| Aug 25, 26 | Liu Cheng | other | 100,000 |
| Aug 25, 26 | Liu Cheng | other | 100,000 |
| Aug 18, 26 | Xu Jiandong | other | 100,000 |
| Aug 18, 26 | Xu Jiandong | other | 100,000 |
| Oct 7, 25 | Xu Jiandong | buy | 1,000 |
| Sep 11, 25 | Xu Jiandong | buy | 100 |
| Sep 22, 25 | Xu Jiandong | buy | 1,000 |
| Sep 22, 25 | Jia Dengyao | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ESLA coverage
Recent articles, reports, and earnings notes.
No research on ESLA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ESLA report →Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional
gurufocus.com · Nov 16
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
businesswire.com · Nov 16
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
businesswire.com · Oct 26
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
businesswire.com · Oct 15
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com · Oct 14
Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1.1% – Should You Buy?
defenseworld.net · Aug 21
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com · Aug 11
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com · Aug 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.